Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall

Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

1982 • 603 citations

Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

1984 • 571 citations

Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.

1985 • 408 citations

Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.

1987 • 340 citations

Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis.

1987 • 251 citations

Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.

1986 • 241 citations

The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.

1987 • 205 citations

Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque

1985 • 183 citations

Immunoglobulins and complement components in human aortic atherosclerotic intima

1985 • 145 citations

Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system

1985 • 143 citations

Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9.

1985 • 139 citations

Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes.

1986 • 138 citations

Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.

1988 • 132 citations

Decay-accelerating factor is present on cultured human umbilical vein endothelial cells.

1986 • 129 citations

Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis

1987 • 116 citations

Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.

1988 • 77 citations

Decay accelerating factor regulates complement activation on glomerular epithelial cells.

1989 • 67 citations

Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.

1987 • 57 citations

Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions.

1989 • 54 citations

[24] Preparation and isolation of specific antibodies to complement components

1983 • 44 citations

Decay‐accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme‐linked immunosorbent assay (ELISA)

1988 • 24 citations

Co-localization of terminal C5b-9 complement complexes and macrophages in human atherosclerotic arterial walls

1988 • 15 citations

Purification and characterization of decay-accelerating factor (DAF) from Raji cells.

1988 • 5 citations